Market reactionShares rose 18% on Nov 6.
Nuvectis Pharma develops ciprocopan, a once-daily oral pill for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder; it is approved in China, not in the United States.
Nuvectis's case centers on ex-China development of ciprocopan, a once-daily oral Factor B inhibitor approved in China for previously untreated PNH. Its U.S. opportunity depends on the development requirements following the planned FDA pre-IND meeting. NXP200's Chinese glioma responses strengthen the oncology opportunity, alongside NXP900 combinations. The July $115 million gross offering supports management's runway guidance into 1H 2029, but spending depends on the development programs required.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: FDA accepts a fast U.S. path for ciprocopan
Will FDA permit a U.S. path built primarily on the Chinese ciprocopan results with limited additional clinical work?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Ciprocopan's U.S. path remains central as NXP200 glioma results expand oncology potential
China-approved oral CFB inhibitor races to define a U.S. path before IND data determine whether foreign Phase 3 alone can support registration
First oral once-daily complement Factor B inhibitor approved in China, now racing to file a U.S. IND — thesis turns on whether ex-China data can anchor an FDA path
NXP100 beat eculizumab decisively in PNH with two filed MAAs in China, but Ex-China rights are licensed-in and NMPA approval determines whether the bet pays off
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Gastrointestinal cancers, Other cancers, Kidney diseases, Blood disorders
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
15 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.